Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fredun Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was ₹3,605 Mil.
Fredun Pharmaceuticals's quarterly Total Liabilities
declined
from Sep. 2025 (₹3,069.26 Mil) to Dec. 2025 (₹0.00 Mil) but then
increased
from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹3,604.61 Mil).
Fredun Pharmaceuticals's annual Total Liabilities
increased
from Mar. 2024 (₹1,861.28 Mil) to Mar. 2025 (₹3,460.29 Mil) and
increased
from Mar. 2025 (₹3,460.29 Mil) to Mar. 2026 (₹3,604.61 Mil).
Fredun Pharmaceuticals Total Liabilities Related Terms
Fredun Pharmaceuticals Total Liabilities Historical Data
* Premium members only.
The historical data trend for Fredun Pharmaceuticals's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fredun Pharmaceuticals Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Fredun Pharmaceuticals's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fredun Pharmaceuticals (BOM:539730) has a Total Liabilities of ₹3,605 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Fredun Pharmaceuticals and its competitors.
Is Fredun Pharmaceuticals' Total Liabilities too high?
Fredun Pharmaceuticals' current Total Liabilities is ₹3,605 Mil. Overall, Fredun Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fredun Pharmaceuticals' Total Liabilities compare to ZTS and UTHR?
Fredun Pharmaceuticals' Total Liabilities of ₹3,605 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Fredun Pharmaceuticals and its competitors. Fredun Pharmaceuticals's current Total Liabilities is ₹3,605 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fredun Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fredun Pharmaceuticals (BOM:539730) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹532.60, compared to a current price of ₹916.60 — trading 72.1% above its estimated fair value. The current Total Liabilities is ₹3,605 Mil. Fredun Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Fredun Pharmaceuticals (BOM:539730), the current Total Liabilities is ₹3,605 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fredun Pharmaceuticals (BOM:539730) Overvalued in 2026?
Based on GuruFocus' analysis, Fredun Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹916.60 is trading 72.1% above its estimated GF Value™ of ₹532.60.
GuruFocus considers Fredun Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:539730:
Total Liabilities: ₹3,605 Mil
GF Value™: ₹532.60 vs. price of ₹916.60 (72.1% above fair value)
No single metric tells the full story. See the BOM:539730 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fredun Pharmaceuticals Ltd in its Endeavour to move ahead has now ventured into manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with Animal Healthcare products also with products ranging from allopathic formulations to on field diagnostic kits, Company's main objective is to be a holistic healthcare provider. The group is dedicated to improving lives of people. The Company operates only in a single segment i.e. Pharmaceutical Segment. The company has presence in Domestic as well as International market. The company generates majority of revenue from Domestic market.
67GF Score
Get the complete analysis for BOM:539730
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539730 has been successfully added to your 
